Track Angiotensin 1‑7 in Peptimes™
Angiotensin 1-7 is a peptide of 7 amino acids, Asp-Arg-Val-Tyr-Ile-His-Pro: the first seven amino acids of angiotensin II. FDA's substance registry lists it as talfirastide, also called TXA127. (Source: FDA's substance registry (GSRS).)
Is Angiotensin 1-7 FDA-approved?
No. Angiotensin 1-7 is investigational: it has been studied in registered clinical trials and isn't FDA-approved for any use.
Angiotensin 1-7
Also: Ang-(1-7), angiotensin-(1-7), talfirastide, TXA127
- Status label in the Peptimes Library
- Phase 2 Trials
- Routes in Peptimes
- SubcutaneousOther
- Updated
- 1 Nov 2026
US regulatory status
FDA status
Not FDA-approved for any use. Drugs@FDA lists no application with angiotensin 1-7 (talfirastide, TXA127) as an active ingredient. Giapreza (angiotensin II) is a different peptide.
Source: Drugs@FDA, checked 1 Nov 2026
Investigational
Yes.
Source: ClinicalTrials.gov, checked 1 Nov 2026
How to track it in Peptimes
Add angiotensin 1-7 in My Protocols and set the schedule you already follow: days of the week, times of day and a start date. Peptimes never suggests an amount when you log or schedule a dose. Its Library entry shows the status label “Phase 2 Trials”, which describes its investigational status. It isn’t an approval.
- Routes: subcutaneous or Other. Choose the one that matches each dose.
- Logging: the amount you took, the route and how you feel.
- Injection sites: subcutaneous doses record the site, and Insights shows where you’ve injected and how recently. It never suggests where to inject next. Doses logged as Other skip this step.
- Reminders and history: reminders at your times, Dose History, the Calendar and CSV or JSON export work as described on the peptide tracker app page.
Peptimes is a tracking app, not medical advice. Talk to a licensed clinician about your treatment. Peptimes doesn’t sell angiotensin 1-7 or any other compound.
More sources
- NIH, ClinicalTrials.gov, studies of TXA127, checked 1 Nov 2026: registered Phase 1 and Phase 2 studies, including NCT04401423, a completed Phase 2 study.
- FDA, Drugs@FDA, checked 1 Nov 2026: no application lists angiotensin 1-7, talfirastide or TXA127 as an active ingredient.
- FDA, Global Substance Registration System, Talfirastide, checked 1 Nov 2026: the sequence Asp-Arg-Val-Tyr-Ile-His-Pro and the names angiotensin 1-7, angiotensin-(1-7), human angiotensin II (1-7) and TXA127.